All news


9 September 2015

Flow Cytometry Boot Camp - 2 day course

Expert Cytometry and the Institut de biologie moléculaire et cellulaire
Present Flow Cytometry Boot Camp - 2 day courseMonday and Tuesday
September 21st and 22nd, 2015
Educational objectives: This two day course will cover the fundamentals of flow cytometry to provide critical concepts for the novice and intermediate user. This course focuses on the core concepts of flow cytometry - the ‘basics’ that every scientist using flow cytometry should know. At the end of this course, students will (...)

Read more

15 June 2015

CNRS innovation medals 2015

The video of Sylviane Muller and her team (Immunobiology and therapy of Lupus) can be viewed on the CNRS video library website
a movie from Marie Mora Chevais, produced by CNRS Images

Read more

28 April 2015

The artificial skin project discussed on Alsace 20, in the show "l’Alsace innovante et créative" (in french)

The artificial skin project highlighted in "l’Alsace innovante et créative", a show broadcasted by Alsace 20.
See below the interview of Vincent Flacher, CNRS researcher in the team "Immune-microenvironment interactions in health and disease" !
Watch the video

Read more

27 February 2015

World Lupus Day Strasbourg 2015

On 10 and 11 may 2015, the CNRS laboratory "Immunopathologie et Chimie Thérapeutique" and the Faculty of Medicine (University of Strasbourg) organize the first french symposium exclusively dedicated to the Lupus.
On this special occasion, eminent and internationally recognized personalities from the field will intervene. Patients’ associations will have a special space reserved for them on Monday from 12:45 to 14:45. The symposium is also open to patients !
The symposium is free of (...)

Read more

9 February 2015

Landmark collaboration agreement and commencement of Immupharma pivotal phase III LupuzorTM study with Simbec-Orion

ImmuPharma and the CRO Simbec-Orion Group have entered into a collaboration to run a Phase III clinical study of the potential lupus treatment Lupuzor.
Luzuzor (also known as Rigerimod, IPP-201101 and P140) is ImmuPharma’s lead compound for the treatment of Lupus, a chronic, potentially life-threatening autoimmune disease. Lupuzor has been granted fast track status by the US FDA and approved to start Phase III trials under a Special Protocol Assessment (SPA) due to its strong safety and (...)

Read more

A noter

 A noter

Immunopathologie et Chimie Thérapeutique
15 Rue R. Descartes
67 084 Strasbourg
Directeur de l'UPR 3572
Sylviane Muller
Isabelle Clauss
Tel: +33 (0)3 88 41 70 19
Fax: +33 (0)3 88 61 06 80
Christian Meier
Tel: +33 (0)3 88 41 70 10
Fax: +33 (0)3 88 61 06 80

   Labex Medalis
Plan d'Accès